ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.

Wei NieZhi-Jie WangKai ZhangBing LiYi-Ran CaiFeng-Cai WenDing ZhangYue-Zong BaiXue-Yan ZhangShu-Yuan WangLei ChengHua ZhongLi LiuJie WangBao-Hui Han

Published in: BMC medicine (2022)

Our study indicated that ctDNA-adjusted bTMB might predict OS benefit in NSCLC patients receiving ICIs. The potential of ctDNA-adjusted bTMB as a noninvasive predictor for immunotherapy should be confirmed in future studies.

Keyphrases

circulating tumor
small cell lung cancer
advanced non small cell lung cancer
brain metastases
current status
risk assessment
epidermal growth factor receptor
tyrosine kinase